{"id":"W3183441818","doi":"10.1002/cncr.33809","title":"Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study","year":2021,"lang":"en","type":"article","venue":"Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Karyopharm Therapeutics; Pharmacyclics; Genentech; Celgene; Daiichi Sankyo Europe; Amgen Canada; Sanofi; GlaxoSmithKline; Spectrum Pharmaceuticals; Amgen; Bristol-Myers Squibb; Regeneron Pharmaceuticals; U.S. Department of Veterans Affairs","keywords":"Medicine; Multiple myeloma; Refractory (planetary science); Term (time); Oncology; Internal medicine; Surgery","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005122397,0.0004891194,0.001553722,0.0004432297,0.0006673018,0.001421983,0.0006903007,0.0009869293,0.001281455],"category_scores_gemma":[0.003720751,0.0002912251,0.002025269,0.0007637689,0.0004043379,0.001222171,0.0009079371,0.001767046,0.0004602109],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009426402,"about_ca_system_score_gemma":0.0006675991,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001164245,"about_ca_topic_score_gemma":0.001394301,"domain_scores_codex":[0.998692,0.0004323169,0.0001525044,0.0002285841,0.0002925925,0.0002020093],"domain_scores_gemma":[0.9947042,0.0007586646,0.00241637,0.0003438984,0.0005767398,0.001200051],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.07923317,0.003278247,0.8619751,0.0004110594,0.003773716,0.0005123426,0.0004946416,0.000923684,0.002393669,0.00009543959,0.003549037,0.04335984],"study_design_scores_gemma":[0.005603433,0.02509201,0.9623557,0.00009836055,0.002053988,0.0005568505,0.0001738635,0.000671376,0.0006157759,0.000123862,0.002601475,0.00005341409],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931486,0.00390908,0.0001926464,0.000237297,0.00003604541,0.0001183823,0.001529232,0.00001388871,0.0008147767],"genre_scores_gemma":[0.9937603,0.0008644978,0.0001542977,0.0003303177,0.00007658624,0.0001391195,0.004282,0.000006739136,0.0003862286],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005122397,"threshold_uncertainty_score":0.02709013,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03730700392493223,"score_gpt":0.2967258337181939,"score_spread":0.2594188297932617,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}